NCT07205523 High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
| NCT ID | NCT07205523 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yigeng Cao,MD,PhD |
| Condition | Hematopoietic Stem Cell Transplantation (HSCT) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2060-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2023-09-01 with a primary completion date of 2060-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023. 2. Planned or actual hematopoietic stem cell transplantation (HSCT). 3. Provision of signed informed consent. Exclusion Criteria: 1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons. 2. Substance abuse compromising adherence. 3. Any condition judged by investigators to jeopardize safety or compliance.
Contact & Investigator
Hui Geng
PRINCIPAL INVESTIGATOR
Affiliated Hospital of Qinghai University
Frequently Asked Questions
Who can join the NCT07205523 clinical trial?
This trial is open to participants of all sexes, studying Hematopoietic Stem Cell Transplantation (HSCT). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07205523 currently recruiting?
Yes, NCT07205523 is actively recruiting participants. Contact the research team at caoyigeng@ihcams.ac.cn for enrollment information.
Where is the NCT07205523 trial being conducted?
This trial is being conducted at Xining, China.
Who is sponsoring the NCT07205523 clinical trial?
NCT07205523 is sponsored by Yigeng Cao,MD,PhD. The principal investigator is Hui Geng at Affiliated Hospital of Qinghai University. The trial plans to enroll 1,000 participants.